US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
ES2283012T3
(es)
|
1996-01-04 |
2007-10-16 |
Novartis Vaccines And Diagnostics, Inc. |
Bacterioferritina de helicobacter pylori.
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
DE69932717T2
(de)
|
1998-05-22 |
2007-08-09 |
Ottawa Health Research Institute, Ottawa |
Methoden und produkte zur induzierung mukosaler immunität
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
JP2003509452A
(ja)
*
|
1999-09-24 |
2003-03-11 |
スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム |
ポリオキシエチレンアルキルエーテル又はエステル及び少なくとも一つのノニオン界面活性剤を含有するアジュバント
|
PL355287A1
(en)
*
|
1999-09-24 |
2004-04-05 |
Smithkline Beecham Biologicals S.A. |
Intranasal influenza virus vaccine
|
EP1311288A1
(en)
*
|
2000-01-20 |
2003-05-21 |
Ottawa Health Research Institute |
Immunostimulatory nucleic acids for inducing a th2 immune response
|
CA2400842C
(en)
|
2000-02-23 |
2013-01-15 |
Smithkline Beecham Biologicals S.A. |
Novel compounds
|
EP1284740B1
(en)
|
2000-05-19 |
2008-05-21 |
Corixa Corporation |
Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with monosaccharide-based compounds
|
CA2413959C
(en)
|
2000-06-20 |
2015-07-07 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
WO2002000174A2
(en)
|
2000-06-28 |
2002-01-03 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
AU2002215914B2
(en)
*
|
2000-10-02 |
2004-08-19 |
Glaxosmithkline Biologicals S.A. |
Split enveloped virus preparation
|
MXPA03003690A
(es)
|
2000-10-27 |
2004-05-05 |
Chiron Spa |
Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
|
CA2430379A1
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
ES2399386T3
(es)
*
|
2001-04-05 |
2013-04-01 |
Novartis Vaccines And Diagnostics, Inc. |
Aumento de la inmunidad de las mucosas tras sensibilización parenteral
|
EP1988097A1
(en)
|
2001-05-09 |
2008-11-05 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
MY134424A
(en)
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
CA2451739A1
(en)
|
2001-06-29 |
2003-01-09 |
Chiron Corporation |
Hcv e1e2 vaccine compositions
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
WO2003053220A2
(en)
|
2001-12-17 |
2003-07-03 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
US8088388B2
(en)
|
2002-02-14 |
2012-01-03 |
United Biomedical, Inc. |
Stabilized synthetic immunogen delivery system
|
US7501134B2
(en)
|
2002-02-20 |
2009-03-10 |
Novartis Vaccines And Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
SE0201701D0
(sv)
*
|
2002-06-05 |
2002-06-05 |
Gotovax Ab |
Treatment of epithelial tumors and infections
|
AU2003276679A1
(en)
|
2002-06-13 |
2003-12-31 |
Chiron Corporation |
Vectors for expression of hml-2 polypeptides
|
ES2306752T3
(es)
*
|
2002-07-24 |
2008-11-16 |
Centre National De La Recherche Scientifique (Cnrs) |
Metodo para indentificar compuestos biologicamente activos con propiedades antiasmaticas y/o antialergicas.
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
US20040132652A1
(en)
*
|
2002-08-30 |
2004-07-08 |
Shire Biochem Inc. |
Pharmaceutical compositions
|
WO2004032958A1
(en)
|
2002-10-11 |
2004-04-22 |
Chiron Srl |
Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
|
EP1556077A2
(en)
|
2002-10-29 |
2005-07-27 |
Coley Pharmaceutical Group, Ltd |
Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
|
EP2279746B1
(en)
|
2002-11-15 |
2013-10-02 |
Novartis Vaccines and Diagnostics S.r.l. |
Surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
JP2006520746A
(ja)
|
2002-12-27 |
2006-09-14 |
カイロン コーポレイション |
リン脂質を含む免疫原性組成物
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
HUE026376T2
(en)
|
2003-01-06 |
2016-05-30 |
Corixa Corp |
Certain aminoalkyl glucosamide phosphate compounds and their use
|
WO2004067030A2
(en)
|
2003-01-30 |
2004-08-12 |
Chiron Srl |
Injectable vaccines against multiple meningococcal serogroups
|
CA2520124A1
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of benzazole compounds for immunopotentiation
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
NZ543467A
(en)
|
2003-04-10 |
2008-07-31 |
Novartis Vaccines & Diagnostic |
The severe acute respiratory syndrome coronavirus
|
PL1631264T5
(pl)
|
2003-06-02 |
2018-09-28 |
Glaxosmithkline Biologicals Sa |
Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
ATE506963T1
(de)
|
2003-10-02 |
2011-05-15 |
Novartis Vaccines & Diagnostic |
Kombinationsimpfstoffe gegen meningitis
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
AU2004308964B2
(en)
|
2003-12-23 |
2010-09-16 |
Arbor Vita Corporation |
Antibodies for oncogenic strains of HPV and methods of their use
|
JP5600375B2
(ja)
|
2004-03-09 |
2014-10-01 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
インフルエンザウイルスワクチン
|
BRPI0510315A
(pt)
|
2004-04-30 |
2007-10-16 |
Chiron Srl |
integração de vacinação com conjugado meningocócico
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
EP2811027A1
(en)
|
2004-05-21 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for RSV and PIV vaccines
|
AU2005285513B2
(en)
|
2004-05-25 |
2011-02-24 |
Oregon Health And Science University |
SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
EP2612679A1
(en)
|
2004-07-29 |
2013-07-10 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
NZ555937A
(en)
|
2005-01-27 |
2009-05-31 |
Childrens Hosp & Res Ct Oak |
GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
SI2351772T1
(sl)
|
2005-02-18 |
2016-11-30 |
Glaxosmithkline Biologicals Sa |
Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
|
CN101203529A
(zh)
|
2005-02-18 |
2008-06-18 |
诺华疫苗和诊断公司 |
来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
|
EP2392349A3
(en)
|
2005-03-31 |
2012-01-18 |
GlaxoSmithKline Biologicals S.A. |
Vaccines against chlamydial infection
|
CN101237881B
(zh)
*
|
2005-08-03 |
2015-04-22 |
伊缪诺金公司 |
免疫偶联物剂型
|
EP2357000A1
(en)
|
2005-10-18 |
2011-08-17 |
Novartis Vaccines and Diagnostics, Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
EP1776963A1
(en)
|
2005-10-19 |
2007-04-25 |
Gbf-Gesellschaft Für Biotechnologische Forschung Mbh |
Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
|
CA2628152C
(en)
|
2005-11-04 |
2016-02-02 |
Novartis Vaccines And Diagnostics S.R.L. |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
WO2007081447A2
(en)
|
2005-11-22 |
2007-07-19 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
DK1976559T6
(da)
|
2006-01-27 |
2020-04-06 |
Seqirus Uk Ltd |
Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
|
ES2536426T3
(es)
|
2006-03-23 |
2015-05-25 |
Novartis Ag |
Compuestos de imidazoquinoxalina como inmunomoduladores
|
EP2004226A1
(en)
|
2006-03-24 |
2008-12-24 |
Novartis Vaccines and Diagnostics GmbH & Co. KG |
Storage of influenza vaccines without refrigeration
|
EP2382988A1
(en)
|
2006-03-31 |
2011-11-02 |
Novartis AG |
Combined mucosal and parenteral immunization against HIV
|
US20110206692A1
(en)
|
2006-06-09 |
2011-08-25 |
Novartis Ag |
Conformers of bacterial adhesins
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
JP2010500399A
(ja)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
尿路病原性大腸菌由来の免疫原
|
EP1897557A1
(en)
|
2006-09-07 |
2008-03-12 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Use of glycolipids as adjuvants
|
CA2663196A1
(en)
|
2006-09-11 |
2008-03-20 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
NZ577405A
(en)
|
2006-12-06 |
2012-08-31 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
DK2136836T3
(en)
|
2007-04-04 |
2017-04-10 |
Infectious Disease Res Inst |
Immunogenic compositions with mycobacterium tuberculosis polypeptides and fusions thereof
|
EA201070066A1
(ru)
|
2007-06-27 |
2010-06-30 |
Новартис Аг |
Вакцины против гриппа с низким содержанием добавок
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
MX2010001284A
(es)
|
2007-08-02 |
2010-08-31 |
Biondvax Pharmaceuticals Ltd |
Vacunas contra la influenza con multiepitope multimerico.
|
CA2695421A1
(en)
|
2007-08-03 |
2009-02-12 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
KR101621837B1
(ko)
|
2007-09-12 |
2016-05-17 |
노파르티스 아게 |
Gas57 돌연변이 항원 및 gas57 항체
|
ES2445755T3
(es)
|
2007-11-07 |
2014-03-05 |
Celldex Therapeutics, Inc. |
Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205)
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
AU2008331800A1
(en)
|
2007-12-03 |
2009-06-11 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
AU2008335457B2
(en)
|
2007-12-07 |
2015-04-16 |
Glaxosmithkline Biologicals S.A. |
Compositions for inducing immune responses
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
CN104292312A
(zh)
|
2007-12-21 |
2015-01-21 |
诺华股份有限公司 |
链球菌溶血素o的突变形式
|
NZ587382A
(en)
|
2008-02-21 |
2012-01-12 |
Novartis Ag |
Meningococcal fhbp polypeptides
|
EP2631245A1
(en)
|
2008-03-10 |
2013-08-28 |
Children's Hospital & Research Center at Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
EP2356225A1
(en)
|
2008-12-03 |
2011-08-17 |
Protea Vaccine Technologies Ltd. |
GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
|
EP2865389A1
(en)
|
2008-12-09 |
2015-04-29 |
Pfizer Vaccines LLC |
IgE CH3 peptide vaccine
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
AU2010204139A1
(en)
|
2009-01-12 |
2011-08-11 |
Novartis Ag |
Cna_B domain antigens in vaccines against gram positive bacteria
|
US8568732B2
(en)
|
2009-03-06 |
2013-10-29 |
Novartis Ag |
Chlamydia antigens
|
PL2510947T3
(pl)
|
2009-04-14 |
2016-09-30 |
|
Kompozycje do immunizacji przeciwko Staphylococcus aureus
|
WO2010125480A1
(en)
|
2009-04-30 |
2010-11-04 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
EP2442826B1
(en)
|
2009-06-15 |
2015-07-08 |
National University of Singapore |
Influenza vaccine, composition, and methods of use
|
SG177533A1
(en)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Conserved escherichia coli immunogens
|
DK3178490T3
(da)
|
2009-07-15 |
2022-06-20 |
Glaxosmithkline Biologicals Sa |
RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse
|
CN102770443A
(zh)
|
2009-07-16 |
2012-11-07 |
诺华有限公司 |
脱毒大肠杆菌免疫原
|
KR20130127547A
(ko)
|
2009-07-30 |
2013-11-22 |
화이자 백신스 엘엘씨 |
항원성 타우 펩타이드 및 이의 용도
|
WO2011024072A2
(en)
|
2009-08-27 |
2011-03-03 |
Novartis Ag |
Hybrid polypeptides including meningococcal fhbp sequences
|
ES2670576T3
(es)
|
2009-09-03 |
2018-05-31 |
Pfizer Vaccines Llc |
Vacuna de PCSK9
|
CA2779798C
(en)
|
2009-09-30 |
2019-03-19 |
Novartis Ag |
Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
BR112012010531A2
(pt)
|
2009-10-27 |
2019-09-24 |
Novartis Ag |
"polipeptídeos de modificação meningocócica fhbp"
|
WO2011056899A2
(en)
|
2009-11-03 |
2011-05-12 |
Ligocyte Pharmaceuticals, Inc. |
Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
SG10201408505SA
(en)
|
2009-12-22 |
2015-02-27 |
Celldex Therapeutics Inc |
Vaccine compositions
|
WO2011080595A2
(en)
|
2009-12-30 |
2011-07-07 |
Novartis Ag |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
ES2910199T3
(es)
|
2010-03-30 |
2022-05-11 |
Childrens Hospital & Res Center At Oakland |
Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011127316A1
(en)
|
2010-04-07 |
2011-10-13 |
Novartis Ag |
Method for generating a parvovirus b19 virus-like particle
|
EP2558069A1
(en)
|
2010-04-13 |
2013-02-20 |
Novartis AG |
Benzonapthyridine compositions and uses thereof
|
EA024701B1
(ru)
|
2010-04-13 |
2016-10-31 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
WO2011154863A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
EP2942061A3
(en)
|
2010-06-07 |
2016-01-13 |
Pfizer Vaccines LLC |
Ige ch3 peptide vaccine
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US20130171185A1
(en)
|
2010-07-06 |
2013-07-04 |
Ethan Settembre |
Norovirus derived immunogenic compositions and methods
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
WO2012064659A1
(en)
|
2010-11-08 |
2012-05-18 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
CN106822882A
(zh)
*
|
2010-12-14 |
2017-06-13 |
葛兰素史密丝克莱恩生物有限公司 |
分枝杆菌抗原组合物
|
EP2655389A2
(en)
|
2010-12-24 |
2013-10-30 |
Novartis AG |
Compounds
|
EP3527224A1
(en)
|
2011-01-26 |
2019-08-21 |
GlaxoSmithKline Biologicals S.A. |
Rsv immunization regimen
|
CN103517713A
(zh)
|
2011-02-22 |
2014-01-15 |
彼昂德瓦克斯医药有限公司 |
在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
PT2707385T
(pt)
|
2011-05-13 |
2017-12-19 |
Glaxosmithkline Biologicals Sa |
Antigénios de f de rsv pré-fusão
|
US20150030586A1
(en)
|
2011-06-21 |
2015-01-29 |
Sarah Ellen Warren |
Compositions and methods for the therapy and diagnosis of cancer
|
EP3854413A1
(en)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
EP2736921B1
(en)
|
2011-07-25 |
2018-06-27 |
GlaxoSmithKline Biologicals SA |
Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2013038385A2
(en)
|
2011-09-14 |
2013-03-21 |
Novartis Ag |
Escherichia coli vaccine combination
|
SG11201402375VA
(en)
|
2011-12-08 |
2014-10-30 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
AU2013224026A1
(en)
|
2012-02-24 |
2014-08-21 |
Novartis Ag |
Pilus proteins and compositions
|
EP2833900B1
(en)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
RU2727476C2
(ru)
|
2012-04-26 |
2020-07-21 |
Новартис Аг |
Антигены и антигенные композиции
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
SG11201406592QA
(en)
|
2012-05-04 |
2014-11-27 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
JP2015518845A
(ja)
|
2012-05-22 |
2015-07-06 |
ノバルティス アーゲー |
髄膜炎菌血清群xコンジュゲート
|
EP2869842A1
(en)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Immunogenic compositions and uses thereof
|
EP4299138A2
(en)
|
2012-08-03 |
2024-01-03 |
Access to Advanced Health Institute |
Compositions and methods for treating an active mycobacterium tuberculosis infection
|
EA201590427A1
(ru)
|
2012-10-02 |
2015-09-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Нелинейные сахаридные конъюгаты
|
US9855324B2
(en)
|
2012-10-03 |
2018-01-02 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
ES2826555T3
(es)
|
2012-11-30 |
2021-05-18 |
Glaxosmithkline Biologicals Sa |
Antígenos de Pseudomonas y combinación de antígenos
|
BR112015024860B1
(pt)
|
2013-03-28 |
2023-11-07 |
Access To Advanced Health Institute |
Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
|
CN112999344A
(zh)
|
2013-05-15 |
2021-06-22 |
阿尔伯达大学董事会 |
E1e2 hcv疫苗及使用方法
|
PL3096785T3
(pl)
|
2014-01-21 |
2021-03-08 |
Pfizer Inc. |
Kompozycje immunogenne zawierające skoniugowane antygeny sacharydów otoczkowych i ich zastosowania
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
WO2016014719A1
(en)
|
2014-07-23 |
2016-01-28 |
Children's Hospital & Research Center Oakland |
Factor h binding protein variants and methods of use thereof
|
AR102548A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
EP3945096A1
(en)
|
2014-12-19 |
2022-02-02 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
EP3244917B1
(en)
|
2015-01-15 |
2023-04-19 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
WO2016145085A2
(en)
|
2015-03-09 |
2016-09-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
RU2017140856A
(ru)
|
2015-05-26 |
2019-06-26 |
Огайо Стейт Инновейшн Фаундейшн |
Стратегия вакцинации против вируса свиного гриппа вакциной на основе наночастиц
|
AU2016271857B2
(en)
|
2015-06-03 |
2020-05-28 |
Affiris Ag |
IL-23-P19 vaccines
|
JP2018522885A
(ja)
|
2015-07-07 |
2018-08-16 |
アフィリス・アクチェンゲゼルシャフトAffiris Ag |
IgE介在性疾患の処置および予防のためのワクチン
|
MY192183A
(en)
|
2015-07-21 |
2022-08-05 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
JP6884145B2
(ja)
|
2015-11-20 |
2021-06-09 |
ファイザー・インク |
肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
|
ES2811523T3
(es)
|
2016-01-19 |
2021-03-12 |
Pfizer |
Vacunas contra el cáncer
|
EA201892362A1
(ru)
|
2016-04-18 |
2019-04-30 |
Селлдекс Терапьютикс, Инк. |
Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
|
MX2018014270A
(es)
|
2016-05-21 |
2019-02-14 |
Infectious Disease Res Inst |
Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
|
US11801290B2
(en)
|
2016-09-16 |
2023-10-31 |
Access To Advanced Health Institute |
Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
CN110198735A
(zh)
|
2017-01-20 |
2019-09-03 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
WO2019035963A1
(en)
|
2017-08-16 |
2019-02-21 |
Ohio State Innovation Foundation |
NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
|
MX2020004543A
(es)
|
2017-11-03 |
2020-09-18 |
Takeda Vaccines Inc |
Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
KR20210011919A
(ko)
|
2018-04-17 |
2021-02-02 |
셀덱스 쎄라퓨틱스, 인크. |
항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2020051766A1
(zh)
|
2018-09-11 |
2020-03-19 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
WO2020123444A1
(en)
|
2018-12-11 |
2020-06-18 |
Celldex Therapeutics, Inc. |
Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
|
JP2022512345A
(ja)
|
2018-12-12 |
2022-02-03 |
ファイザー・インク |
免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
KR20220092572A
(ko)
|
2019-11-01 |
2022-07-01 |
화이자 인코포레이티드 |
에스케리키아 콜라이 조성물 및 그 방법
|
NL2030835B1
(en)
|
2020-01-24 |
2022-12-29 |
Aim Immunotech Inc |
Methods, compositions, and vaccinces for treating a virus infection
|
CA3171864A1
(en)
|
2020-02-21 |
2021-08-26 |
Pfizer Inc. |
Purification of saccharides
|
CN115605498A
(zh)
|
2020-02-23 |
2023-01-13 |
辉瑞公司(Us) |
大肠杆菌组合物及其方法
|
EP4114848A4
(en)
|
2020-02-26 |
2024-04-03 |
Versitech Limited |
PD-1-BASED VACCINES AGAINST CORONAVIRUS INFECTION
|
CA3189834A1
(en)
*
|
2020-07-24 |
2022-01-27 |
Ronald Levy |
A three component vaccine for covid-19
|
MX2023004912A
(es)
|
2020-10-27 |
2023-05-16 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
KR20230097160A
(ko)
|
2020-11-04 |
2023-06-30 |
화이자 인코포레이티드 |
폐렴구균 백신에 사용하기 위한 면역원성 조성물
|
WO2022101745A2
(en)
|
2020-11-10 |
2022-05-19 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
IL305313A
(en)
|
2021-02-19 |
2023-10-01 |
Sanofi Pasteur |
Recombinant meningococcal B vaccine
|
CN117545773A
(zh)
|
2021-04-09 |
2024-02-09 |
塞德斯医疗公司 |
抗ilt4的抗体、双特异性抗ilt4/pd-l1抗体及其用途
|
WO2022234483A1
(en)
|
2021-05-04 |
2022-11-10 |
King Abdullah University Of Science And Technology |
Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
|
TW202306969A
(zh)
|
2021-05-28 |
2023-02-16 |
美商輝瑞大藥廠 |
包含結合之莢膜醣抗原的免疫原組合物及其用途
|
BR112023023671A2
(pt)
|
2021-05-28 |
2024-02-06 |
Pfizer |
Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023079529A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
CA3237496A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
KR102420201B1
(ko)
*
|
2022-01-17 |
2022-07-13 |
주식회사 유이케미칼 |
인지질 외피 보유 바이러스 사멸기능을 가지는 친환경 방역 조성물
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024018061A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
WO2024110839A2
(en)
|
2022-11-22 |
2024-05-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
WO2024130009A1
(en)
|
2022-12-14 |
2024-06-20 |
Yale University |
Compositions and methods of use thereof for the treatment of virally driven cancers
|